AEGiS-PRn: Protein Sciences Announces Contact With The National Institute of Allergy and Infectious Diseases for Production of New HIV/AIDS Vaccines: Over $2 Million in Funding Already Approved and up to $76 Million Could Be Accessed

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Protein Sciences Announces Contact With The National Institute of Allergy and Infectious Diseases for Production of New HIV/AIDS Vaccines: Over $2 Million in Funding Already Approved and up to $76 Million Could Be Accessed

PRNewswire - December 12, 2001

MERIDEN, Conn., Dec. 12 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced today that it has signed a contract with the National Institute of Allergy and Infections Diseases (NIAID) that provides for up to $76 million in funding through mid-2006 for development and production of antigens for new vaccines for HIV/AIDS. Under the contract, after NIAID approves a vaccine candidate it will issue a task order to fund Protein Sciences to develop and manufacture clinical materials suitable for Phase I, II and III human clinical trials. Industry and institutions in the U.S or abroad qualify for funding.

Manon Cox, PSC's Vice President, Corporate and Process Development, commented, "Our Company has a long history of involvement in developing HIV/AIDS vaccines, and we have extensive experience in producing clinical materials to support large scale human clinical trials using our proprietary baculovirus expression vector technology. Many companies have been reluctant to develop new vaccines for this dreaded disease because of economic considerations and this contract makes it possible to obtain government funding for a significant part of the development cost." She added, "We already have received task orders for over $2 million in funding for p55 and a synthetic protein being developed by a biotechnology company. The approval process is straightforward and rapid, and we strongly encourage companies and institutions to take advantage of this opportunity."

Founded in 1983, Protein Sciences Corporation

(http://www.proteinsciences.com) is the world leader in developing genes coding for proteins into commercial human and veterinary vaccines, therapeutics and diagnostics using its proprietary baculovirus expression vector system (BEVS) technology that includes its patented expresSF+(R) serum free, high yielding, scalable insect cell line. Customers access PSC's proprietary BEVS technology through its GeneXpress(R) program. This allows them to obtain cGMP human and animal clinical materials more reliably, rapidly and less expensively than through alternative protein expression systems.

SOURCE Protein Sciences Corporation Web Site: http://www.proteinsciences.com

011212
PR011213

Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .